Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

NCT06444815 is registered in ClinicalTrials.gov with KaliVir Immunotherapeutics as lead sponsor.

NCT NCT06444815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06444815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
Lead sponsor
KaliVir Immunotherapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
September 16, 2024
Completion date
December 31, 2027
Enrollment
60 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, cutaneous squamous cell carcinoma (cscc), head and neck squamous cell carcinoma, kidney cancer, melanoma stage iv, merkel cell carcinoma of skin, mesothelioma, microsatellite stable colorectal cancer, non-small cell lung cancer, renal cell carcinoma, solid tumor, adult, squamous cell carcinoma, urothelial carcinoma bladder